Hear from A/Prof. Kerry Hitos (Director of the Westmead Research Centre for Evaluation of Surgical Outcomes, USyd), and Prof. Christopher Ward (Clinical haematologist, RNS Hospital), on treatment and management of disease in Australia, such as VTE.
Professor Chris Ward: "Where we've still got work to do is in developing the tools for risk assessment".
A "3 bucket" model approach is recommended by A/Prof. Kerry Hitos for assessing VTE risk in surgical patients.
VTE = venous thromboembolism.
Date of preparation: March 2019. SM_SAN980. SAANZ.ENO.19.01.0069
*Clexane Safety Lock as an automatic safety lock system.
Further information is available on request from Sanofi.
sanofi-aventis australia pty ltd training as Sanofi, ABN 31 008 558 807, Talavera Corporate Centre, Building D, 12-24 Talavera Road, Macquarie Park, NSW 2113. ®Clexane is a registered trademark of sanofi-aventis.
Receive future issues of Anticoagulation Matters, compiled specifically for you.
Access patient information and resources on VTE and Clexane®.